$GEL

Taylor Jack T sold (to issuer) $38K of GEL

Taylor Jack T sold (to issuer) 2,575 shares of GENESIS ENERGY LP (GEL) at $14.77 on 2026-07-01.

Original reporting
SEC EDGAR · Taylor Jack T
Published Jul 2, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GEL
Neutral
medium confidence
Mentioned
$GEL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GELNeutralLow
01

Why it matters

The disclosure updates ownership records but does not include new business performance, guidance, or legal/regulatory developments.

02

Market read

Traders may note the insider sale, but the event is unlikely to drive a material repricing without corroborating catalysts.

03

What to watch

The transaction is a sale to the issuer (often tied to buyback/plan mechanics), and the disclosed size (~$38K) is usually not informative about long-term valuation.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update on 2026-07-02 for a 2026-07-01 insider sale

Background

The filing is an SEC Form 4 insider transaction for a director of Genesis Energy LP.

Company-level read

Ticker impact

$GELNeutralMedium confidence
Context

Genesis Energy LP director Taylor Jack T sold 2,575 shares to the issuer at $14.77/share for ~$38.0K, per Form 4 filed today.

Expected impact

Low likelihood of a sustained price move; any near-term impact is likely noise unless repeated or paired with other disclosures.

Evidence & confidence

Form 4 insider transactions are primary-source but this is a small dollar amount relative to company size and provides no new operating/regulatory/financial catalyst.

Market effects

Minimal; insider sale does not change sector fundamentals or guidance.

None indicated.

None indicated.

Counterpoint

No 10b5-1 plan is disclosed; if this pattern continues, it could be interpreted as management reducing exposure rather than routine liquidity.

Key entities

  • GENESIS ENERGY LP

    Subject of the Form 4 insider transaction; director sold shares to the issuer.

  • Taylor Jack T

    Director who sold 2,575 shares at $14.7700/share on 2026-07-01.

Related articles

$GELMed

Genesis Energy Q2 Earnings Call Highlights

Genesis Energy (NYSE:GEL) said it reduced borrowings on its $900 million senior secured credit facility to zero and retired about $218 million of Series A preferred securities in 1H 2026. It issued $750 million 6.75% notes due 2034 and redeemed 7.75% notes due 2028, targeting ~$25 million lower annualized all-in cost of capital. Quarterly distribution rose to $0.20.

$GELMed

Genesis Energy (NYSE:GEL) Delivers Strong Q2 CY2026 Numbers

Genesis Energy (NYSE:GEL) reported Q2 2026 results. Revenue rose 41% year on year to $532 million, beating Wall Street estimates by 26.2%, and GAAP profit was $0.26 per share above consensus. The article also cites adjusted EBITDA margin of 32.2% and free cash flow margin averaging -2.8% over five years, with shares up 2.4% to $15.21 after the release.

$GELMedAI 8/10

GENESIS ENERGY LP (GEL): Results of Operations and Financial Condition

GENESIS ENERGY LP (GEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a90ex9918kearnings_q22026.htm EX-99.1 Document FOR IMMEDIATE RELEASE August 6, 2026 Genesis Energy, L.P. Reports Second Quarter 2026 Results HOUSTON – (BUSINESS WIRE) – Genesis Energy, L.P. (NYSE: GEL) today announced its second quarter results. We generated the followi

$GELMed

Nifty, Sensex Continue to Push Higher: Tuesday Market Report

Tuesday’s BSE saw 2,293 stocks rise, 1,967 fall and 169 unchanged (advance/decline 1.16). On NSE, 83 issues hit 52-week highs while 28 closed at 52-week lows; Nifty Metal, Auto and Pharma led losers, while Nifty IT, FMCG and Media led gainers. Key corporate moves: Sonata Software NCLT-approved merger; Zydus Lifesciences to buy Assertio at $23.50/share; HCLTech invests ₹1,427.25 crore in Sarvam AI.